Concepts (117)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Robotic Surgical Procedures | 4 | 2025 | 161 | 2.880 |
Why?
|
| Pneumonectomy | 4 | 2025 | 113 | 2.690 |
Why?
|
| Lung Neoplasms | 12 | 2025 | 674 | 2.450 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2025 | 166 | 1.390 |
Why?
|
| Esophagectomy | 3 | 2024 | 48 | 1.280 |
Why?
|
| Esophageal Neoplasms | 2 | 2024 | 83 | 1.190 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2014 | 345 | 1.180 |
Why?
|
| Thoracic Surgical Procedures | 2 | 2025 | 40 | 1.010 |
Why?
|
| Conversion to Open Surgery | 1 | 2025 | 13 | 0.940 |
Why?
|
| Thoracic Surgery, Video-Assisted | 1 | 2025 | 61 | 0.910 |
Why?
|
| Thoracic Surgery | 2 | 2025 | 77 | 0.900 |
Why?
|
| Resuscitation | 1 | 2025 | 72 | 0.900 |
Why?
|
| Databases, Factual | 3 | 2025 | 873 | 0.880 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2025 | 129 | 0.870 |
Why?
|
| Anastomotic Leak | 1 | 2024 | 35 | 0.850 |
Why?
|
| Pain, Postoperative | 1 | 2025 | 162 | 0.840 |
Why?
|
| Frailty | 2 | 2022 | 130 | 0.820 |
Why?
|
| General Surgery | 1 | 2025 | 211 | 0.780 |
Why?
|
| Societies, Medical | 1 | 2025 | 379 | 0.780 |
Why?
|
| Education, Medical, Graduate | 1 | 2025 | 352 | 0.760 |
Why?
|
| Retrospective Studies | 15 | 2025 | 6659 | 0.710 |
Why?
|
| Robotics | 1 | 2022 | 87 | 0.690 |
Why?
|
| Quality Improvement | 2 | 2024 | 443 | 0.650 |
Why?
|
| Analgesics, Opioid | 1 | 2025 | 536 | 0.640 |
Why?
|
| Neoplasm Staging | 7 | 2021 | 509 | 0.620 |
Why?
|
| Opioid-Related Disorders | 1 | 2025 | 507 | 0.560 |
Why?
|
| Internship and Residency | 1 | 2025 | 808 | 0.550 |
Why?
|
| Aged | 14 | 2025 | 14449 | 0.500 |
Why?
|
| Adenocarcinoma | 3 | 2014 | 348 | 0.450 |
Why?
|
| Male | 17 | 2025 | 29893 | 0.420 |
Why?
|
| Carcinoid Tumor | 1 | 2013 | 13 | 0.410 |
Why?
|
| Emergencies | 2 | 2025 | 121 | 0.400 |
Why?
|
| Humans | 22 | 2025 | 63449 | 0.380 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2013 | 259 | 0.380 |
Why?
|
| Female | 15 | 2025 | 32883 | 0.370 |
Why?
|
| Middle Aged | 10 | 2025 | 17615 | 0.370 |
Why?
|
| Risk Assessment | 4 | 2024 | 2079 | 0.330 |
Why?
|
| Postoperative Complications | 3 | 2025 | 1308 | 0.320 |
Why?
|
| Clinical Competence | 2 | 2025 | 727 | 0.300 |
Why?
|
| United States | 4 | 2025 | 7843 | 0.290 |
Why?
|
| New York | 3 | 2014 | 144 | 0.240 |
Why?
|
| Adult | 8 | 2025 | 16826 | 0.230 |
Why?
|
| Delphi Technique | 1 | 2025 | 101 | 0.230 |
Why?
|
| Risk Factors | 4 | 2024 | 5354 | 0.230 |
Why?
|
| Survival Rate | 4 | 2014 | 851 | 0.230 |
Why?
|
| Propensity Score | 1 | 2025 | 160 | 0.220 |
Why?
|
| Incidence | 4 | 2021 | 1377 | 0.220 |
Why?
|
| Reoperation | 1 | 2025 | 293 | 0.210 |
Why?
|
| Consensus | 1 | 2025 | 208 | 0.210 |
Why?
|
| Stomach | 1 | 2024 | 87 | 0.210 |
Why?
|
| Giant Cell Tumor of Bone | 1 | 2023 | 8 | 0.210 |
Why?
|
| Esophageal Diseases | 1 | 2023 | 16 | 0.200 |
Why?
|
| Morbidity | 1 | 2022 | 113 | 0.190 |
Why?
|
| Elective Surgical Procedures | 1 | 2022 | 124 | 0.190 |
Why?
|
| Bone Neoplasms | 1 | 2023 | 125 | 0.190 |
Why?
|
| Follow-Up Studies | 4 | 2014 | 2459 | 0.180 |
Why?
|
| Curriculum | 1 | 2025 | 599 | 0.180 |
Why?
|
| Logistic Models | 1 | 2024 | 1276 | 0.170 |
Why?
|
| Time Factors | 4 | 2014 | 3768 | 0.160 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 141 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2022 | 338 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2021 | 1644 | 0.150 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 2576 | 0.140 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 322 | 0.140 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2681 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2025 | 5680 | 0.130 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 772 | 0.130 |
Why?
|
| Prognosis | 3 | 2014 | 1749 | 0.110 |
Why?
|
| Thoracic Neoplasms | 1 | 2014 | 13 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2014 | 49 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 373 | 0.100 |
Why?
|
| Mediastinal Neoplasms | 1 | 2013 | 20 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2013 | 226 | 0.100 |
Why?
|
| Positron-Emission Tomography | 1 | 2013 | 208 | 0.100 |
Why?
|
| Neoadjuvant Therapy | 1 | 2012 | 87 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2013 | 206 | 0.090 |
Why?
|
| Models, Statistical | 1 | 2013 | 308 | 0.090 |
Why?
|
| Aged, 80 and over | 4 | 2013 | 5463 | 0.090 |
Why?
|
| Smoking | 1 | 2014 | 866 | 0.080 |
Why?
|
| Disease Progression | 1 | 2013 | 1173 | 0.080 |
Why?
|
| Length of Stay | 1 | 2012 | 812 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2021 | 422 | 0.060 |
Why?
|
| Young Adult | 2 | 2013 | 4695 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2021 | 937 | 0.060 |
Why?
|
| Radius | 1 | 2023 | 16 | 0.050 |
Why?
|
| Lymphatic Metastasis | 2 | 2013 | 88 | 0.050 |
Why?
|
| Necrosis | 1 | 2023 | 144 | 0.050 |
Why?
|
| Hematoxylin | 1 | 2022 | 11 | 0.050 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2022 | 12 | 0.050 |
Why?
|
| Cause of Death | 2 | 2014 | 221 | 0.050 |
Why?
|
| Endosonography | 1 | 2022 | 26 | 0.050 |
Why?
|
| Cytodiagnosis | 1 | 2022 | 46 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 2 | 2013 | 279 | 0.050 |
Why?
|
| Interrupted Time Series Analysis | 1 | 2021 | 28 | 0.050 |
Why?
|
| Brazil | 1 | 2021 | 100 | 0.050 |
Why?
|
| Preoperative Period | 1 | 2020 | 71 | 0.040 |
Why?
|
| Preoperative Care | 1 | 2020 | 193 | 0.040 |
Why?
|
| Walking | 1 | 2020 | 238 | 0.040 |
Why?
|
| Medicare | 1 | 2021 | 612 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 956 | 0.030 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2013 | 2 | 0.030 |
Why?
|
| Mediastinoscopy | 1 | 2013 | 8 | 0.030 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2013 | 98 | 0.030 |
Why?
|
| Radionuclide Imaging | 1 | 2012 | 125 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 189 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 89 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 17 | 0.020 |
Why?
|
| New York City | 1 | 2012 | 80 | 0.020 |
Why?
|
| Multimodal Imaging | 1 | 2012 | 68 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 242 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2012 | 240 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 443 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2012 | 583 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2012 | 730 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2012 | 448 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2012 | 877 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 2570 | 0.020 |
Why?
|